FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Dal Poggetto John
2. Issuer Name and Ticker or Trading Symbol

Sonoma Pharmaceuticals, Inc. [ SNOA ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Financial Officer
(Last)          (First)          (Middle)

C/O SONOMA PHARMACEUTICALS, INC., 1129 N. MCDOWELL BLVD
3. Date of Earliest Transaction (MM/DD/YYYY)

12/31/2019
(Street)

PETALUMA, CA 94954
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock option (right to buy) $4.36 12/31/2019  A   13000     (1)12/31/2029 Common stock 13000  (2)18496 D  

Explanation of Responses:
(1) The options vest in two equal tranches: the first half vest on 7/1/2020 and the remaining half vest on 12/31/2020.
(2) The options were awarded and granted to Mr. Dal Poggetto for services performed.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Dal Poggetto John
C/O SONOMA PHARMACEUTICALS, INC.
1129 N. MCDOWELL BLVD
PETALUMA, CA 94954


Chief Financial Officer

Signatures
/s/ John Dal Poggetto1/3/2020
**Signature of Reporting PersonDate

Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
Von Feb 2024 bis Mär 2024 Click Here for more Sonoma Pharmaceuticals Charts.
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
Von Mär 2023 bis Mär 2024 Click Here for more Sonoma Pharmaceuticals Charts.